Georgina V. Long, MD, PhD, on Advanced Melanoma: RELATIVITY-098 in Completely Resected Disease

Posted: Thursday, June 19, 2025

Georgina V. Long, MD, PhD, of Melanoma Institute Australia, discusses the primary results from RELATIVITY-098, which evaluated the PD-1 inhibitor nivolumab plus the LAG3 inhibitor relatlimab vs nivolumab alone as adjuvant therapeutic options for patients with completely resected stage III–IV melanoma.

---